NAV
35.11(-0.37%)Fund Size (CR)
₹1,239.57Expense Ratio
0.71Scheme Type
Active FundValue Research
-
Min. investment
₹5,000Minimum Additional Investment
₹1,000Minimum SIP Investment
₹100Minimum Withdrawal
₹500Exit Load
0.25%Return Since Launch
13.18%
Basic Details
Scheme Manager
Rajat Srivastava
Bench Mark
BSE Healthcare TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | 20 February 2026 | 10121.18 | 1.21% | - | -0.49% | 124/987 |
| 1 Month | 27 January 2026 | 10516.81 | 5.17% | - | 2.74% | 277/964 |
| 3 Month | 27 November 2025 | 9803.56 | -1.96% | - | -2.25% | 477/944 |
| 6 Month | 26 August 2025 | 9809.84 | -1.90% | - | 1.78% | 639/916 |
| 1 Year | 27 February 2025 | 11281.56 | 12.82% | 12.82% | 16.11% | 527/848 |
| 3 Year | 27 February 2023 | 19813.72 | 98.14% | 25.57% | 20.41% | 100/514 |
| 5 Year | 26 February 2021 | 22563.26 | 125.63% | 17.65% | 16.71% | 148/426 |
| Since Inception | 28 December 2015 | 35239.30 | 252.39% | 13.18% | 11.01% | 492/987 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | 3 March 2025 | 1,30,000 | 132450.63 | 1.89% | 1.89% |
| 3 Year | 3 April 2023 | 3,60,000 | 440326.88 | 22.31% | 6.94% |
| 5 Year | 1 April 2021 | 6,00,000 | 896007.99 | 49.33% | 8.35% |
| 10 Year | 1 April 2016 | 12,00,000 | 3021194.77 | 151.77% | 9.67% |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
Monthly Investment (₹)
Expected Returns Rate (%)
Time Period (in Years)
Invested Amount
₹25,000
Estimated Returns
₹19,059
76%
Returns
Future value of your investment
₹44,059
Risk Ratios
4.60%
Standard Deviation
0.92%
Beta
1.08%
Sharpe Ratio
-0.02%
Treynor's Ratio
11.53%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 9.31% | 723130 | 115.36 | Equity | Pharmaceuticals |
| Max Healthcare | 6.24% | 807996 | 77.31 | Equity | Healthcare |
| Abbott India | 5.98% | 26881 | 74.10 | Equity | Pharmaceuticals |
| Divi's Lab. | 5.37% | 110044 | 66.59 | Equity | Pharmaceuticals |
| Health.Global | 5.14% | 1075346 | 63.67 | Equity | Healthcare |
| Apollo Hospitals | 4.97% | 88528 | 61.62 | Equity | Healthcare |
| Cipla | 4.69% | 438828 | 58.10 | Equity | Pharmaceuticals |
| Rainbow Child. | 3.75% | 408375 | 46.48 | Equity | Healthcare |
| Mankind Pharma | 3.38% | 196981 | 41.84 | Equity | Pharmaceuticals |
| Bayer Crop Sci. | 3.34% | 92824 | 41.46 | Equity | Agro Chemicals |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund - Direct (G) | 1239.57 | 5.17% | -1.96% | -1.90% | 12.82% | 25.57% | |
| Nippon India Taiwan Equity Fund - Direct (G) | 448.04 | 17.96% | 33.40% | 53.02% | 100.62% | 45.69% | |
| Nippon India Taiwan Equity Fund - Direct (IDCW) | 448.04 | 17.96% | 33.40% | 53.02% | 100.62% | 45.69% | |
| HDFC Defence Fund - Direct (G) | 7793.88 | 8.24% | 3.24% | 8.83% | 49.84% | - | |
| HDFC Defence Fund - Direct (IDCW) | 7793.88 | 8.24% | 3.24% | 8.83% | 49.84% | - | |
| Franklin Asian Equity Fund - Direct (G) | 371.57 | 5.18% | 16.09% | 26.14% | 40.83% | 17.86% |
List of Schemes under Tata Mutual Fund
News
Tata Mutual Fund announces change in Exit Load Structure
Tata Mutual Fund has announced change in exit load structure under following scheme stands revised with effect from March 02, 2026Change in Exit Load:
Name of the Scheme Existing Exit Load Revised Exit Load Tata Arbitrage Fund 0.25 % of the applicable NAV, if redeemed/ switched out/withdrawn on or before expiry of 30 Days from the date of allotment. 0.25 % of the applicable NAV, if redeemed/ switched out/withdrawn on or before expiry of 15 Days from the date of allotment. Powered by Capital Market - Live News
Tata MF announces Income Distribution cum capital withdrawal (IDCW) under its scheme
Tata Mutual Fund has announced 04 February 2026 as the record date for declaration of Income Distribution cum capital withdrawal (IDCW) under the monthly IDCW option and under the Periodic IDCW Periodic-Payout/Reinvestment) of following schemes. The amount of IDCW (Rs per unit) on the face value of Rs 10 per unit will be:Tata Aggressive Hybrid Fund ' Regular Plan & Direct Plan: 0.36 each.
Powered by Capital Market - Live News
Tata Mutual Fund announces change in Key Personnel
Tata Mutual Fund has announced that Mr. Akshay Kumar Rao has been appointed as Head of Products & Strategy with effect from February 23, 2026 ('Effective Date').Details of Mr. Akshay Kumar Rao,
Age: 36 years
Designation: Head of Products & Strategy
Qualification: Post Graduate in Strategy and Finance from Indian School of Business, Mohali. Chartered Accountant from ICAI, Mumbai. Bachelor of Commerce from Mumbai University. .
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
4 December 2015
Total AUM (Cr)
₹1239.57
Tata India Pharma & Healthcare Fund - Direct (G) is an Sectoral / Thematic-oriented fund from the renowned AMC, Tata Mutual Fund. Launched in 4 December 2015, this fund is managed by Rajat Srivastava. With assets under management (AUM) worth ₹1,239.57 (Cr), as of 2 March 2026, Tata India Pharma & Healthcare Fund - Direct (G) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 13.18% since its launch.
The current NAV of Tata India Pharma & Healthcare Fund - Direct (G) is ₹35.11, as on 2 March 2026. The fund's benchmark index is BSE Healthcare TRI. You can invest in Tata India Pharma & Healthcare Fund - Direct (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹100 while the minimum lumpsum investment is ₹5,000.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
The fund has generated 25.57% and 17.65% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 99.10% in Equity, 0.18% in Debt and 0.72% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 58.26% in Pharmaceuticals & Biotech, 36.70% in Healthcare Services, 3.69% in Fertilisers & Agrochemica, 1.18% in Cash & Others, 0.14% in Debt
